EBM Technologies Incorporated (8409) Fair Value & Analysis
Healthcare · TW · Market cap 611M TWD
Fair value as of: Jun 24, 2026
Analysis
EBM Technologies Incorporated (8409) currently trades at 19.10 TWD, while our model-based Fair Value estimate is 7.20 TWD — implying the stock looks roughly 62.3% overvalued today. We read business quality at 95/100 (high quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium — the entry price still matters most (evidence: medium).
About the company
EBM Technologies Incorporated engages in the development and marketing of software and integrity solutions to the health sector in Taiwan and internationally. The company offers Enterprise PACS (picture archiving and communication systems) solutions, including SoliPACS that unites various products of the radiology, mammography, and dental fields; SoliPACS Gateway, a DICOM gateway; SoliPACS Server, an interface between HIS and RIS patient data and PACS; SoliPACS Web Viewer, which enables radiologists and physicians to view, compare, utilize, and select DICOM-compliant images; SoliPACS Report, offers a tool for generating customized reports; and Advanced Server Archive, a PACS storage system. It also provides UDE (Ubiquitous Diagnostic Environment) App, which converts standard iPad Pro into a standalone DICOM server, viewer, display, and Al all in one; MobiPACS Server to store, process, and retrieve image files for mobile devices; MobiPACS App, an in mobile medical image viewing app; …
Open the full interactive analysis →
Similar stocks
Frequently asked questions
Is EBM Technologies Incorporated (8409) undervalued?
What is the fair value of 8409?
What is the quality score of 8409?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.
Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.